SCHEDULE: RTW Investments Discloses 7.2% Stake in uniQure N.V.

RTW Investments, LP and its Managing Partner, Roderick Wong, M.D., have disclosed a 7.2% beneficial ownership stake in uniQure N.V. ordinary shares.

Summary

• RTW Investments, LP and Roderick Wong, M.D. (collectively, the "Reporting Persons") beneficially own 4,424,968 ordinary shares of uniQure N.V.
• This ownership represents 7.2% of uniQure N.V.'s total outstanding ordinary shares.
• The percentage is calculated based on 54,866,930 shares outstanding as of July 24, 2025, plus an additional 6,736,841 shares issued from a public offering that closed on August 15, 2025.
• The Reporting Persons share both voting and dispositive power over all 4,424,968 beneficially owned shares.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of uniQure N.V., except for activities solely in connection with a nomination under Rule 14a-11.

Sentiment

Score: 7

Explanation: The disclosure of a 7.2% beneficial ownership by a specialized healthcare investment firm like RTW Investments is generally a positive signal, indicating confidence in uniQure N.V. The statement that the shares were acquired in the ordinary course of business supports a long-term investment thesis. However, the explicit mention of potential activities 'solely in connection with a nomination under Rule 14a-11' introduces a slight element of potential future shareholder activism, which could be viewed with mixed sentiment depending on the context.

Positives

• A significant stake of 7.2% by RTW Investments, LP, a specialized healthcare investment firm, signals confidence in uniQure N.V.'s long-term prospects.
• The investment is stated to be in the ordinary course of business, suggesting a strategic, long-term holding rather than a short-term speculative position.

Risks

• The Reporting Persons explicitly state that the shares were not acquired for the purpose of changing or influencing control, 'other than activities solely in connection with a nomination under Rule 14a-11.' This clause indicates a potential for future engagement in director nominations, which could lead to governance challenges or changes if the Reporting Persons disagree with current management or board decisions.

Future Outlook

The filing does not provide forward-looking statements or guidance from uniQure N.V. or the Reporting Persons regarding the company's future performance or strategic direction, beyond the implication of a long-term investment.

Industry Context

This Schedule 13G filing indicates a significant investment by a specialized healthcare fund, RTW Investments, in uniQure N.V., a biotechnology company. Such filings are common in the biotech sector where institutional investors often take substantial positions in companies with promising pipelines or technologies. A 7.2% stake suggests a notable conviction in uniQure's potential, aligning with a trend of focused investments in innovative life sciences firms.

Corporate Governance

Stakeholder Impact

• Shareholders: The disclosure of a significant institutional investor holding a 7.2% stake could instill confidence and potentially attract other investors, positively impacting share price. The potential for future board nominations could also lead to governance improvements or strategic shifts.
• Management/Board: The presence of a large, potentially active investor could increase scrutiny on management performance and strategic decisions, especially given the clause about potential director nominations.

Key Dates

Recommendation

This Schedule 13G filing primarily discloses a significant beneficial ownership stake by RTW Investments, LP in uniQure N.V. While the 7.2% stake by a specialized healthcare investor is a positive signal of confidence in the company's long-term prospects, the filing itself does not provide new financial performance data or strategic updates from uniQure N.V. to warrant a 'buy' or 'sell' recommendation. The mention of potential activities related to director nominations under Rule 14a-11 suggests a watchful 'hold' stance, as future actions by this significant shareholder could influence the company's direction. Investors should monitor uniQure N.V.'s operational performance and any further communications from RTW Investments.

Keywords

uniQure N.V., RTW Investments, Roderick Wong, Beneficial Ownership, Schedule 13G, Ordinary Shares, Institutional Investor, Healthcare Investment, Biotechnology, Shareholder Stake